Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
does anyone know why we are up 10 per cent today? it is certainly a pleasant surprise.
big move up or down coming... in a downtrend for a year now. The trend is not my friend. Need good Q3 numbers to reverse the trend.
Not one to use technical analysis much, but the Bollinger Bands on AUPH are as tight as a Megaship going through the Panama Canal.
Yes , we do and you know what that is, no need to elaborate.
Jess, my hunch is you and Cervelo have a lot in common…….
and look at him stay around. Wow, can’t figure it out.
and look at her run.
On the daily chart, the hammer candlestick on 9/8 could be the bottom. We have another hammer candlestick on 9/23 with a higher low. Todays close was great, if we can stay above this and breakthrough the $8 resistance we could be on our way up. This is definitely not financial advice, it is TA bullsh*t lol
The script count is completely inaccurate and we will only know when announced. Last Q with revs at $28M was not bad. But the EU approval payout will bump up rev for Q3. Even a flat quarter of sales we still will report around $55M. It will bring a lot more investors that just look at numbers. A blowout Q of $68M is possible IMO.
$MYOV Sweet sweet redemption. I hope many of my $AUPH friends made the move to MYOV a couple months ago. I think final price tag will be north of $30. Still holding full position. https://t.co/KCkaWTo2tG
— JG (@BioLunacyJG) October 5, 2022
Cosa, when you say you are looking forward to the ER, is it because you have been seeing rising scripts? Or some other reason?
Looking forward to the ER next month. Hoping we will push to over $10. Might not be for long as a lot of people are probably going to make an exit.
More free options. Not sure who it went to, nothing on SEC website yet.
Not sure why October $9 strike volume is so heavy. I think that's going to go to $0
Does anyone know how long it typically takes for PATB to respond to appeals? AUPH filed the appeal on August 9th as the per the link below. Checking online, I see conflicting information with regards to response time lasting from 2 months to 15 months.
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2022-00617%2F12
Grabbed more shares today. Looking forward to our Q3 $65M
All the WEF/Biden admin needs to do is turn the oil back on…
Those who sell now, in my opinion, are plain idiots.
Thanks Jess. I get a kick out of the title saying that these stocks are to be sold NOW, but then it details this guy selling them in the 2nd quarter. We are at the end of the 3rd quarter and almost all the stocks mentioned have been beaten down. Wrong time to sell.
Best post of the day:
“I was wondering where you were Cervelo!! Felt like the news was too positive so you had to manufacture something up in your mind eh?
You forgot to mention the CEO's salary in your message.”
His departure was rather abrupt.
Probably a bad point, I have swing shares stuck at $9.90 range from 3 months ago lol. Writing calls to slowly make it back.
yak that is a good response thank you.
I would hope that being the case that management would/should have thanked him for all his hard work in moving the company forward and his diligent work in the company achieving EU approval and anything else he offered while on the Bod.
I wish the market saw the EU approval as good news, share price would have moved up.
We will just have to remain ecstatic with our continued 27.00 loss after BMY announced their position to present a BO.
Things could be worse I could of jumped on the emotional redbox rollercoaster and lost 100%
10 stocks to sell now.
https://finance.yahoo.com/news/10-stocks-sell-now-according-174147199.html
I was wondering where you were Cervelo!! Felt like the news was too positive so you had to manufacture something up in your mind eh?
You forgot to mention the CEO's salary in your message.
It appears that Walbert was there only to (help) secure EU approval, and, with this accomplished, he is moving on. The fact that the resignation happened the same day as the EU approval, and that it was effective immediately, supports this thesis.
In general, directors' compensation is not tied to specific milestones, though it is possible.
There may also have been a "gentleman's agreement" to the effect of "help us get through EU approval" and then we'll go our separate ways.
since the company wrote that and not Mr. Walbert as he was leaving I would read it correctly as such. Otherwise why not make his own reason for departure.
Mr. Walbert's departure from the Board is due to disagreement with the Company and the Board in matters relating to the operations, policies and practices of the Company.
Then again it is only my opinion which I am not allowed to have here.
On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022. Mr. Walbert's departure from the Board is not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.
Above is from the recent 8-k
Jess, I think that if that was the case, someone would have latched on to AURINIA by now….
What Director left??
Excellent point Cosa, could not agree more
It’s not too far fetched that Voclosporin may one day become a potential candidate in treating Alzheimer’s disease IF the speculation in the article below holds true that Alzheimer’s disease is caused by overactive immune system within the brain. Why not, it is being considered in ARDS anyway…jmo.
https://www.sciencealert.com/alzheimers-might-not-actually-be-a-brain-disease-expert-says
I will defer to U as the board expert on the EU reimbursement process … so good luck .
In Germany they can probably launch while they negotiate… at least for the first 6 months
Kiwi
Yes, this was all priced in. No reason yet for the market to get excited. Sales are extremely slow here in the States and we (as does the market) know that Europe is a lot tougher than the U.S.
The reimbursement negotiations not only will depressing from the perspective that the EU countries will want to pay very little, but it will take a lot of time. So becoming profitable is not in the cards in the very near future.
What hopefully this means though, is that some prospective buyer gets or remains interested, seeing acceptance of the drug worldwide and we can get made whole here.
Jess etc all, does the departure of the director have any impact for or against the assumption of merger talks in the background? Have any you seen this in past mergers?
thx, Longbear
50% swing opportunity here. The 3rd quarter rev in November will blow estimates out of the water. We know it is because of the EMA approval deal, but most others don't look at why, they only look at the $ compared to last ER report.
Was EU approval in doubt ? The challenge is reimbursement negotiations.
Ask poster RMB ( Rosemouth) … he knows the road map for EU / UK reimbursement decisions
Kiwi
Nope. The issues with KZR are
1) no significant data until ASH early Nov
2) will they need one or two P3 trials for FDA approval
One trial to match Lupkynis P3 trial … ie includes induction therapy
The other to match KZR’s P 2 trial but on a larger scale … ie mainly refractory patients
IMHO. Both ( if there’s 2 ) will mandate steroid tapering
Risk of dilution if they go with 2 P3 trials
Kiwi
Longbear. Thanks for that link. I bought a block based on that link. Funny how the price moves on just buying in 1,000 share lots. Not like the good old days where you could buy and sell and it wouldn’t move.
Jess, I bought in on 9/15 as my post indicates. You should follow the thread..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169960791
Geez BR. How could anyone believe you anymore? You’re giving us especially zzaatt plenty of ammunition. You dumped your non-existent shares with a slight gain?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169788470
Its a sell the news event
Weak market response so I dumped my shares just now for a very slight gain……Some day…
This PR was expected since 9/15. Its delay is what caused many (including me) to hope for the merger news at last. I really hope that news is in the making and will be out soon. Until then however given how crazy market is we might see dips... Fingers crossed, holding strong since after ARIA.
This is big news, oddly quiet on the trading side though.
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |